Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refr...

Full description

Saved in:
Bibliographic Details
Published inThe lancet oncology Vol. 21; no. 8; pp. 1099 - 1109
Main Authors Apolo, Andrea B, Nadal, Rosa, Tomita, Yusuke, Davarpanah, Nicole N, Cordes, Lisa M, Steinberg, Seth M, Cao, Liang, Parnes, Howard L, Costello, Rene, Merino, Maria J, Folio, Les R, Lindenberg, Liza, Raffeld, Mark, Lin, Jeffrey, Lee, Min-Jung, Lee, Sunmin, Alarcon, Sylvia V, Yuno, Akira, Dawson, Nancy A, Allette, Kimaada, Roy, Arpita, De Silva, Dinuka, Lee, Molly M, Sissung, Tristan M, Figg, William D, Agarwal, Piyush K, Wright, John J, Ning, Yangmin M, Gulley, James L, Dahut, William L, Bottaro, Donald P, Trepel, Jane B
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2020
Elsevier Limited
Subjects
Online AccessGet full text
ISSN1470-2045
1474-5488
1474-5488
DOI10.1016/S1470-2045(20)30202-3

Cover

Abstract Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma. This study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA). Eligible patients were 18 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance scale index of 60% or higher, and documented disease progression after at least one previous line of platinum-based chemotherapy (platinum-refractory). Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two additional cohorts that enrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare histologies of the genitourinary tract) were exploratory. Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate by RECIST in cohort one. Response was assessed in all patients who met the eligibility criteria and who received at least 8 weeks of therapy. All patients who received at least one dose of cabozantinib were included in the safety analysis. This completed study is registered with ClinicalTrials.gov, NCT01688999. Between Sept 28, 2012, and Oct, 20, 2015, 68 patients were enrolled on the study (49 in cohort one, six in cohort two, and 13 in cohort three). All patients received at least one dose of cabozantinib. The median follow-up was 61·2 months (IQR 53·8–70·0) for the 57 patients evaluable for response. In the 42 evaluable patients in cohort one, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9–34). The most common grade 3–4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), proteinuria (four [6%]), and hypophosphataemia (four [6%]). There were no treatment-related deaths. Cabozantinib has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. Cabozantinib has innate and adaptive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeutic strategies. National Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.
AbstractList SummaryBackgroundCabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma. MethodsThis study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA). Eligible patients were 18 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance scale index of 60% or higher, and documented disease progression after at least one previous line of platinum-based chemotherapy (platinum-refractory). Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two additional cohorts that enrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare histologies of the genitourinary tract) were exploratory. Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate by RECIST in cohort one. Response was assessed in all patients who met the eligibility criteria and who received at least 8 weeks of therapy. All patients who received at least one dose of cabozantinib were included in the safety analysis. This completed study is registered with ClinicalTrials.gov, NCT01688999. FindingsBetween Sept 28, 2012, and Oct, 20, 2015, 68 patients were enrolled on the study (49 in cohort one, six in cohort two, and 13 in cohort three). All patients received at least one dose of cabozantinib. The median follow-up was 61·2 months (IQR 53·8–70·0) for the 57 patients evaluable for response. In the 42 evaluable patients in cohort one, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9–34). The most common grade 3–4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), proteinuria (four [6%]), and hypophosphataemia (four [6%]). There were no treatment-related deaths. InterpretationCabozantinib has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. Cabozantinib has innate and adaptive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeutic strategies. FundingNational Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.
Summary Background Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma. Methods This study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA). Eligible patients were 18 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance scale index of 60% or higher, and documented disease progression after at least one previous line of platinum-based chemotherapy (platinum-refractory). Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two additional cohorts that enrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare histologies of the genitourinary tract) were exploratory. Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate by RECIST in cohort one. Response was assessed in all patients who met the eligibility criteria and who received at least 8 weeks of therapy. All patients who received at least one dose of cabozantinib were included in the safety analysis. This completed study is registered with ClinicalTrials.gov, NCT01688999. Findings Between Sept 28, 2012, and Oct, 20, 2015, 68 patients were enrolled on the study (49 in cohort one, six in cohort two, and 13 in cohort three). All patients received at least one dose of cabozantinib. The median follow-up was 61·2 months (IQR 53·8–70·0) for the 57 patients evaluable for response. In the 42 evaluable patients in cohort one, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9–34). The most common grade 3–4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), proteinuria (four [6%]), and hypophosphataemia (four [6%]). There were no treatment-related deaths. Interpretation Cabozantinib has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. Cabozantinib has innate and adaptive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeutic strategies. Funding National Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.
Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma. This study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA). Eligible patients were 18 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance scale index of 60% or higher, and documented disease progression after at least one previous line of platinum-based chemotherapy (platinum-refractory). Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two additional cohorts that enrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare histologies of the genitourinary tract) were exploratory. Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate by RECIST in cohort one. Response was assessed in all patients who met the eligibility criteria and who received at least 8 weeks of therapy. All patients who received at least one dose of cabozantinib were included in the safety analysis. This completed study is registered with ClinicalTrials.gov, NCT01688999. Between Sept 28, 2012, and Oct, 20, 2015, 68 patients were enrolled on the study (49 in cohort one, six in cohort two, and 13 in cohort three). All patients received at least one dose of cabozantinib. The median follow-up was 61·2 months (IQR 53·8-70·0) for the 57 patients evaluable for response. In the 42 evaluable patients in cohort one, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9-34). The most common grade 3-4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), proteinuria (four [6%]), and hypophosphataemia (four [6%]). There were no treatment-related deaths. Cabozantinib has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. Cabozantinib has innate and adaptive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeutic strategies. National Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.
Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma.BACKGROUNDCabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T cells and myeloid-derived suppressor cells. In this study, we examined the activity of cabozantinib in patients with metastatic platinum-refractory urothelial carcinoma.This study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA). Eligible patients were 18 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance scale index of 60% or higher, and documented disease progression after at least one previous line of platinum-based chemotherapy (platinum-refractory). Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two additional cohorts that enrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare histologies of the genitourinary tract) were exploratory. Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate by RECIST in cohort one. Response was assessed in all patients who met the eligibility criteria and who received at least 8 weeks of therapy. All patients who received at least one dose of cabozantinib were included in the safety analysis. This completed study is registered with ClinicalTrials.gov, NCT01688999.METHODSThis study was an open-label, single-arm, three-cohort phase 2 trial done at the National Cancer Institute (Bethesda, MD, USA). Eligible patients were 18 years or older, had histologically confirmed urothelial carcinoma or rare genitourinary tract histologies, Karnofsky performance scale index of 60% or higher, and documented disease progression after at least one previous line of platinum-based chemotherapy (platinum-refractory). Cohort one included patients with metastatic urothelial carcinoma with measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Two additional cohorts that enrolled in parallel (patients with bone-only urothelial carcinoma metastases and patients with rare histologies of the genitourinary tract) were exploratory. Patients received cabozantinib 60 mg orally once daily in 28-day cycles until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate by RECIST in cohort one. Response was assessed in all patients who met the eligibility criteria and who received at least 8 weeks of therapy. All patients who received at least one dose of cabozantinib were included in the safety analysis. This completed study is registered with ClinicalTrials.gov, NCT01688999.Between Sept 28, 2012, and Oct, 20, 2015, 68 patients were enrolled on the study (49 in cohort one, six in cohort two, and 13 in cohort three). All patients received at least one dose of cabozantinib. The median follow-up was 61·2 months (IQR 53·8-70·0) for the 57 patients evaluable for response. In the 42 evaluable patients in cohort one, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9-34). The most common grade 3-4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), proteinuria (four [6%]), and hypophosphataemia (four [6%]). There were no treatment-related deaths.FINDINGSBetween Sept 28, 2012, and Oct, 20, 2015, 68 patients were enrolled on the study (49 in cohort one, six in cohort two, and 13 in cohort three). All patients received at least one dose of cabozantinib. The median follow-up was 61·2 months (IQR 53·8-70·0) for the 57 patients evaluable for response. In the 42 evaluable patients in cohort one, there was one complete response and seven partial responses (objective response rate 19%, 95% CI 9-34). The most common grade 3-4 adverse events were fatigue (six [9%] patients), hypertension (five [7%]), proteinuria (four [6%]), and hypophosphataemia (four [6%]). There were no treatment-related deaths.Cabozantinib has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. Cabozantinib has innate and adaptive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeutic strategies.INTERPRETATIONCabozantinib has single-agent clinical activity in patients with heavily pretreated, platinum-refractory metastatic urothelial carcinoma with measurable disease and bone metastases and is generally well tolerated. Cabozantinib has innate and adaptive immunomodulatory properties providing a rationale for combining cabozantinib with immunotherapeutic strategies.National Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.FUNDINGNational Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.
Author Dahut, William L
Cao, Liang
Lindenberg, Liza
Lin, Jeffrey
Figg, William D
Nadal, Rosa
Cordes, Lisa M
Dawson, Nancy A
Gulley, James L
Apolo, Andrea B
Raffeld, Mark
Sissung, Tristan M
Alarcon, Sylvia V
Lee, Min-Jung
Davarpanah, Nicole N
Merino, Maria J
Ning, Yangmin M
Costello, Rene
Lee, Sunmin
Lee, Molly M
Tomita, Yusuke
Yuno, Akira
Wright, John J
Parnes, Howard L
Agarwal, Piyush K
Steinberg, Seth M
Roy, Arpita
Folio, Les R
Allette, Kimaada
Bottaro, Donald P
De Silva, Dinuka
Trepel, Jane B
Author_xml – sequence: 1
  givenname: Andrea B
  surname: Apolo
  fullname: Apolo, Andrea B
  email: andrea.apolo@nih.gov
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 2
  givenname: Rosa
  surname: Nadal
  fullname: Nadal, Rosa
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 3
  givenname: Yusuke
  surname: Tomita
  fullname: Tomita, Yusuke
  organization: Developmental Therapeutics Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 4
  givenname: Nicole N
  surname: Davarpanah
  fullname: Davarpanah, Nicole N
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 5
  givenname: Lisa M
  surname: Cordes
  fullname: Cordes, Lisa M
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 6
  givenname: Seth M
  surname: Steinberg
  fullname: Steinberg, Seth M
  organization: Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
– sequence: 7
  givenname: Liang
  surname: Cao
  fullname: Cao, Liang
  organization: Genetics Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 8
  givenname: Howard L
  surname: Parnes
  fullname: Parnes, Howard L
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 9
  givenname: Rene
  surname: Costello
  fullname: Costello, Rene
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 10
  givenname: Maria J
  surname: Merino
  fullname: Merino, Maria J
  organization: Laboratory of Pathology, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 11
  givenname: Les R
  surname: Folio
  fullname: Folio, Les R
  organization: Radiology and Imaging Sciences, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 12
  givenname: Liza
  surname: Lindenberg
  fullname: Lindenberg, Liza
  organization: Molecular Imaging Program, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 13
  givenname: Mark
  surname: Raffeld
  fullname: Raffeld, Mark
  organization: Laboratory of Pathology, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 14
  givenname: Jeffrey
  surname: Lin
  fullname: Lin, Jeffrey
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 15
  givenname: Min-Jung
  surname: Lee
  fullname: Lee, Min-Jung
  organization: Developmental Therapeutics Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 16
  givenname: Sunmin
  surname: Lee
  fullname: Lee, Sunmin
  organization: Developmental Therapeutics Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 17
  givenname: Sylvia V
  surname: Alarcon
  fullname: Alarcon, Sylvia V
  organization: Developmental Therapeutics Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 18
  givenname: Akira
  surname: Yuno
  fullname: Yuno, Akira
  organization: Developmental Therapeutics Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 19
  givenname: Nancy A
  surname: Dawson
  fullname: Dawson, Nancy A
  organization: Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington DC, USA
– sequence: 20
  givenname: Kimaada
  surname: Allette
  fullname: Allette, Kimaada
  organization: Genitourinary Malignancies Branch, Center for Cancer Research, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 21
  givenname: Arpita
  surname: Roy
  fullname: Roy, Arpita
  organization: Urologic Oncology Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 22
  givenname: Dinuka
  surname: De Silva
  fullname: De Silva, Dinuka
  organization: Urologic Oncology Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 23
  givenname: Molly M
  surname: Lee
  fullname: Lee, Molly M
  organization: Urologic Oncology Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 24
  givenname: Tristan M
  surname: Sissung
  fullname: Sissung, Tristan M
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 25
  givenname: William D
  surname: Figg
  fullname: Figg, William D
  organization: Genitourinary Malignancies Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 26
  givenname: Piyush K
  surname: Agarwal
  fullname: Agarwal, Piyush K
  organization: Urologic Oncology Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 27
  givenname: John J
  surname: Wright
  fullname: Wright, John J
  organization: Genitourinary Malignancies Branch, Center for Cancer Research, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 28
  givenname: Yangmin M
  surname: Ning
  fullname: Ning, Yangmin M
  organization: Genitourinary Malignancies Branch, Center for Cancer Research, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 29
  givenname: James L
  surname: Gulley
  fullname: Gulley, James L
  organization: Developmental Therapeutics Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 30
  givenname: William L
  surname: Dahut
  fullname: Dahut, William L
  organization: Developmental Therapeutics Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 31
  givenname: Donald P
  surname: Bottaro
  fullname: Bottaro, Donald P
  organization: Urologic Oncology Branch, Magnuson Clinical Center, Bethesda, MD, USA
– sequence: 32
  givenname: Jane B
  surname: Trepel
  fullname: Trepel, Jane B
  organization: Developmental Therapeutics Branch, Magnuson Clinical Center, Bethesda, MD, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32645282$$D View this record in MEDLINE/PubMed
BookMark eNqNkl2L1DAYhYusuB_6E5SANytsNR9tmllRkcEvWPBi9Tqk6VsnayapSeoyXvjbTafrXAwMepOmL-c8nJzktDhy3kFRPCb4OcGEv7gmVYNLiqv6nOJnDFNMS3avOMnjqqwrIY62-1lyXJzGeIMxaQiuHxTHjPKqpoKeFL-XqvW_lEvGmRYZhwaVDLgU0a1JKzTY_OvGdRmgD0onHzZoDUnFlOcajcGnFVijLNIqaOP8Wl0i5ZAfwJVWtWAvUDTum4VSZ2qACzSsVAREUQrZ9rC43ysb4dHd96z4-v7dl-XH8urzh0_Lt1elrqtFKntoa1pTvuCsrRcCRLtQmla04l1HOGF51NaKVQKoaDRueiYUdJiLvm1Y3xN2VvCZO7pBbW6VtXIIZq3CRhIsp0JlnNqSU1t5kdtCJcvG89k4BP9jhJjk2kQN1ioHfowyh2CY86YSWfp0T3rjx-DysbKKYdwwLnBWPblTje0aul2Mv1eSBS9ngQ4-xty71GZq2-f6lLG7vNcH8tZ77v1zHvK9mX2Qb-GngSCjzu9AQ2cC6CQ7b_5JeL1H0DY_Kq3sd9hA3HVBZKQSz5CJQfGWMAFeHQb8R4A_HFztHg
CitedBy_id crossref_primary_10_1016_S1470_2045_20_30236_9
crossref_primary_10_1200_JCO_23_02233
crossref_primary_10_1158_1078_0432_CCR_20_2891
crossref_primary_10_1038_s43018_025_00922_5
crossref_primary_10_3389_fonc_2022_877635
crossref_primary_10_3390_cancers14071795
crossref_primary_10_3390_ph14010028
crossref_primary_10_1007_s10147_021_01959_z
crossref_primary_10_18027_2224_5057_2022_12_2_45_51
crossref_primary_10_3390_ijms23073830
crossref_primary_10_1002_cam4_5290
crossref_primary_10_1111_1759_7714_13772
crossref_primary_10_1016_j_ctrv_2021_102333
crossref_primary_10_3390_biomedicines12020413
crossref_primary_10_1080_14656566_2022_2150966
crossref_primary_10_1016_S1470_2045_22_00278_9
crossref_primary_10_1016_S1470_2045_24_00095_0
crossref_primary_10_1016_j_ctarc_2022_100663
crossref_primary_10_1016_j_urolonc_2023_05_012
crossref_primary_10_3390_cancers16172998
crossref_primary_10_1016_j_hoc_2021_02_010
crossref_primary_10_1080_14740338_2024_2429475
crossref_primary_10_1016_j_clgc_2021_04_001
crossref_primary_10_3233_BLC_220030
crossref_primary_10_3390_diagnostics11040640
crossref_primary_10_1200_JCO_21_00939
crossref_primary_10_1007_s40265_022_01802_3
crossref_primary_10_1093_oncolo_oyab056
crossref_primary_10_1016_j_nanoso_2024_101177
crossref_primary_10_17650_1726_9776_2023_19_2_111_126
crossref_primary_10_3233_BLC_200377
crossref_primary_10_1177_03915603221139907
crossref_primary_10_3390_ijms232213723
crossref_primary_10_1177_17588359221108691
crossref_primary_10_2217_fon_2023_0353
crossref_primary_10_3390_cancers13215562
crossref_primary_10_1177_23523735241296763
crossref_primary_10_1177_17588359221094879
crossref_primary_10_3389_fonc_2022_796407
crossref_primary_10_3390_cells11020310
crossref_primary_10_3390_medicina60030398
crossref_primary_10_3390_cancers16132398
crossref_primary_10_1016_j_jbo_2021_100405
crossref_primary_10_3389_fimmu_2024_1472772
crossref_primary_10_1159_000531787
crossref_primary_10_3390_cancers15194886
crossref_primary_10_1007_s11654_021_00295_y
crossref_primary_10_1053_j_ackd_2021_09_003
crossref_primary_10_3390_ijms22020747
crossref_primary_10_1093_jnci_djae017
crossref_primary_10_1080_14737140_2021_1855981
crossref_primary_10_2217_fon_2021_0570
crossref_primary_10_1016_j_ejmech_2024_116283
crossref_primary_10_1056_NEJMoa2026982
crossref_primary_10_1158_1078_0432_CCR_21_3726
crossref_primary_10_1038_s41571_023_00826_2
crossref_primary_10_1038_s41591_024_03086_4
crossref_primary_10_3389_fimmu_2022_933847
crossref_primary_10_3389_fphar_2023_1340401
crossref_primary_10_1016_j_clgc_2021_12_008
crossref_primary_10_1177_17588359221107112
Cites_doi 10.1056/NEJMoa1613683
10.1056/NEJMoa040766
10.1093/jnci/dju033
10.1089/thy.2013.0621
10.1126/science.aac9407
10.1200/JCO.2016.70.7398
10.1111/bju.12437
10.1016/S0140-6736(16)00561-4
10.1200/JCO.2016.71.6795
10.1189/jlb.3A0513-242R
10.1016/j.bone.2015.08.003
10.1200/JCO.2012.48.4659
10.1016/j.ejrad.2015.05.026
10.1200/JCO.19.01140
10.1200/JCO.2009.25.4599
10.1056/NEJMoa1717002
10.1016/j.clgc.2012.10.001
10.1200/JCO.2012.42.5215
10.1634/theoncologist.2016-0229
10.1038/s41571-019-0175-7
10.1200/JCO.2005.07.757
10.1016/j.clgc.2016.05.010
10.1200/JCO.2011.37.3571
10.1097/CAD.0b013e32835efe78
10.1016/S1470-2045(17)30616-2
10.1056/NEJMoa1510016
10.2967/jnumed.116.177295
10.3844/ajisp.2012.1.9
10.1016/S0140-6736(16)32455-2
10.1001/jamadermatol.2014.2734
10.1158/1078-0432.CCR-06-0250
10.1007/s00259-019-04483-5
10.1016/S1470-2045(17)30065-7
ContentType Journal Article
Copyright 2020 Elsevier Ltd
Elsevier Ltd
Copyright © 2020 Elsevier Ltd. All rights reserved.
2020. Elsevier Ltd
Copyright_xml – notice: 2020 Elsevier Ltd
– notice: Elsevier Ltd
– notice: Copyright © 2020 Elsevier Ltd. All rights reserved.
– notice: 2020. Elsevier Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
0TZ
3V.
7RV
7TO
7X7
7XB
88E
8AO
8C1
8C2
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
H94
K9.
KB0
M0S
M1P
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
ADTOC
UNPAY
DOI 10.1016/S1470-2045(20)30202-3
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Pharma and Biotech Premium PRO
ProQuest Central (Corporate)
Nursing & Allied Health Database
Oncogenes and Growth Factors Abstracts
Health & Medical Collection (ProQuest)
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Public Health Database
Lancet Titles
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Medical Database
Nursing & Allied Health Premium
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Pharma and Biotech Premium PRO
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
Lancet Titles
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Pharma and Biotech Premium PRO
MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1474-5488
EndPage 1109
ExternalDocumentID oai:pubmedcentral.nih.gov:8236112
32645282
10_1016_S1470_2045_20_30202_3
S1470204520302023
1_s2_0_S1470204520302023
Genre Clinical Trial, Phase II
Research Support, N.I.H., Intramural
Journal Article
Research Support, N.I.H., Extramural
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation National Cancer Institute Intramural Program and the Cancer Therapy Evaluation Program.
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: ZIA BC010666
– fundername: Intramural NIH HHS
  grantid: ZIA BC011594
GroupedDBID ---
--K
--M
-RU
.1-
.55
.FO
0R~
123
1B1
1P~
1~5
29L
4.4
457
4CK
4G.
53G
5VS
6PF
7-5
71M
7RV
7X7
88E
8AO
8C1
8C2
8FI
8FJ
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAMRU
AAQFI
AAQQT
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
ABBQC
ABMAC
ABMZM
ABUWG
ABWVN
ACGFS
ACIEU
ACPRK
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADMUD
ADNMO
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFKRA
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AHMBA
AIGII
AIIUN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BENPR
BKEYQ
BKOJK
BNPGV
BPHCQ
BVXVI
CCPQU
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
EX3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
FYUFA
G-Q
GBLVA
HMCUK
HVGLF
HZ~
IHE
J1W
KOM
M1P
M41
MO0
N9A
NAPCQ
O-L
O9-
OC~
OO-
OZT
P-8
P-9
P2P
PCD
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
R2-
ROL
RPZ
SDG
SEL
SES
SPCBC
SSH
SSZ
T5K
TLN
UKHRP
UV1
WOW
X7M
XBR
Z5R
3V.
AACTN
AFCTW
AFKWA
AJOXV
ALIPV
AMFUW
RIG
SDF
AAYXX
ACLOT
CITATION
~HD
AGRNS
CGR
CUY
CVF
ECM
EIF
NPM
0TZ
7TO
7XB
8FK
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
ADTOC
UNPAY
ID FETCH-LOGICAL-c549t-feb52526963b598e8b9ac24246dd161398eb5a348e287c07f38aed068fb73ff13
IEDL.DBID UNPAY
ISSN 1470-2045
1474-5488
IngestDate Mon Sep 15 08:16:07 EDT 2025
Sun Sep 28 11:52:57 EDT 2025
Wed Aug 13 08:00:28 EDT 2025
Mon Jul 21 06:06:36 EDT 2025
Wed Oct 01 02:33:57 EDT 2025
Thu Apr 24 23:02:40 EDT 2025
Tue Oct 01 07:16:38 EDT 2024
Tue Feb 25 20:02:54 EST 2025
Tue Aug 26 16:33:28 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
License Copyright © 2020 Elsevier Ltd. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c549t-feb52526963b598e8b9ac24246dd161398eb5a348e287c07f38aed068fb73ff13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
OpenAccessLink https://proxy.k.utb.cz/login?url=https://www.ncbi.nlm.nih.gov/pmc/articles/8236112
PMID 32645282
PQID 2430073680
PQPubID 46089
PageCount 11
ParticipantIDs unpaywall_primary_10_1016_s1470_2045_20_30202_3
proquest_miscellaneous_2423066748
proquest_journals_2430073680
pubmed_primary_32645282
crossref_citationtrail_10_1016_S1470_2045_20_30202_3
crossref_primary_10_1016_S1470_2045_20_30202_3
elsevier_sciencedirect_doi_10_1016_S1470_2045_20_30202_3
elsevier_clinicalkeyesjournals_1_s2_0_S1470204520302023
elsevier_clinicalkey_doi_10_1016_S1470_2045_20_30202_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-08-01
PublicationDateYYYYMMDD 2020-08-01
PublicationDate_xml – month: 08
  year: 2020
  text: 2020-08-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle The lancet oncology
PublicationTitleAlternate Lancet Oncol
PublicationYear 2020
Publisher Elsevier Ltd
Elsevier Limited
Publisher_xml – name: Elsevier Ltd
– name: Elsevier Limited
References Yavuz, Apolo, Kummar (bib29) 2014; 24
Sharma, Retz, Siefker-Radtke (bib4) 2017; 18
Krege, Rexer, vom Dorp (bib15) 2014; 113
Togashi, Shitara, Nishikawa (bib35) 2019; 16
Rosenberg, Hoffman-Censits, Powles (bib3) 2016; 387
Zuo, Apolo, DiGiovanna (bib30) 2015; 151
Choueiri, Escudier, Powles (bib17) 2015; 373
Tolaney, Ziehr, Guo (bib31) 2017; 22
Hanna, Cekic, Sag (bib32) 2015; 350
Balar, Castellano, O'Donnell (bib8) 2017; 18
Bellmunt, Choueiri, Fougeray (bib26) 2010; 28
Galsky, Hahn, Powles (bib13) 2013; 11
Lim, Lindenberg, Mena (bib20) 2020; 47
Rosenberg, Ballman, Halabi (bib11) 2019; 37
Elisei, Schlumberger, Muller (bib18) 2013; 31
Folio, Turkbey, Steinberg, Apolo (bib24) 2015; 84
Siefker-Radtke, Necchi, Park (bib9) 2018; 36
Haider, Hunter, Robinson (bib28) 2015; 81
Rosenberg, O'Donnell, Balar (bib10) 2019; 37
Apolo, Karzai, Trepel (bib23) 2017; 15
Apolo, Infante, Balmanoukian (bib6) 2017; 35
Abou-Alfa, Meyer, Cheng (bib19) 2018; 379
Bellmunt, de Wit, Vaughn (bib5) 2017; 376
Graham, Box, Tunariu (bib27) 2014; 106
Balar, Apolo, Ostrovnaya (bib12) 2013; 31
Cristofanilli, Budd, Ellis (bib25) 2004; 351
De Santis, Bellmunt, Mead (bib2) 2012; 30
Chen, Liu, Hsu (bib33) 2014; 96
Lin, Bradshaw, Perk (bib21) 2016; 57
Gerullis, Eimer, Ecke, Georgas, Arndt, Otto (bib14) 2013; 24
Balar, Galsky, Rosenberg (bib7) 2017; 389
Choueri, Halabi, Sanford (bib16) 2017; 35
Athauda, Giubellino, Coleman (bib22) 2006; 12
Luo, Askeland, Newton, O'Donnell (bib34) 2012; 8
von der Maase, Sengelov, Roberts (bib1) 2005; 23
Galsky (10.1016/S1470-2045(20)30202-3_bib13) 2013; 11
Bellmunt (10.1016/S1470-2045(20)30202-3_bib26) 2010; 28
Zuo (10.1016/S1470-2045(20)30202-3_bib30) 2015; 151
Hanna (10.1016/S1470-2045(20)30202-3_bib32) 2015; 350
Apolo (10.1016/S1470-2045(20)30202-3_bib6) 2017; 35
Graham (10.1016/S1470-2045(20)30202-3_bib27) 2014; 106
Lin (10.1016/S1470-2045(20)30202-3_bib21) 2016; 57
Yavuz (10.1016/S1470-2045(20)30202-3_bib29) 2014; 24
Rosenberg (10.1016/S1470-2045(20)30202-3_bib10) 2019; 37
Abou-Alfa (10.1016/S1470-2045(20)30202-3_bib19) 2018; 379
Cristofanilli (10.1016/S1470-2045(20)30202-3_bib25) 2004; 351
Gerullis (10.1016/S1470-2045(20)30202-3_bib14) 2013; 24
Togashi (10.1016/S1470-2045(20)30202-3_bib35) 2019; 16
Choueri (10.1016/S1470-2045(20)30202-3_bib16) 2017; 35
Rosenberg (10.1016/S1470-2045(20)30202-3_bib3) 2016; 387
Lim (10.1016/S1470-2045(20)30202-3_bib20) 2020; 47
Haider (10.1016/S1470-2045(20)30202-3_bib28) 2015; 81
Balar (10.1016/S1470-2045(20)30202-3_bib7) 2017; 389
Balar (10.1016/S1470-2045(20)30202-3_bib12) 2013; 31
Bellmunt (10.1016/S1470-2045(20)30202-3_bib5) 2017; 376
Siefker-Radtke (10.1016/S1470-2045(20)30202-3_bib9) 2018; 36
Athauda (10.1016/S1470-2045(20)30202-3_bib22) 2006; 12
Balar (10.1016/S1470-2045(20)30202-3_bib8) 2017; 18
Sharma (10.1016/S1470-2045(20)30202-3_bib4) 2017; 18
Apolo (10.1016/S1470-2045(20)30202-3_bib23) 2017; 15
von der Maase (10.1016/S1470-2045(20)30202-3_bib1) 2005; 23
Folio (10.1016/S1470-2045(20)30202-3_bib24) 2015; 84
De Santis (10.1016/S1470-2045(20)30202-3_bib2) 2012; 30
Elisei (10.1016/S1470-2045(20)30202-3_bib18) 2013; 31
Rosenberg (10.1016/S1470-2045(20)30202-3_bib11) 2019; 37
Krege (10.1016/S1470-2045(20)30202-3_bib15) 2014; 113
Choueiri (10.1016/S1470-2045(20)30202-3_bib17) 2015; 373
Tolaney (10.1016/S1470-2045(20)30202-3_bib31) 2017; 22
Chen (10.1016/S1470-2045(20)30202-3_bib33) 2014; 96
Luo (10.1016/S1470-2045(20)30202-3_bib34) 2012; 8
32645283 - Lancet Oncol. 2020 Aug;21(8):1005-1006. doi: 10.1016/S1470-2045(20)30236-9.
References_xml – volume: 16
  start-page: 356
  year: 2019
  end-page: 371
  ident: bib35
  article-title: Regulatory T cells in cancer immunosuppression - implications for anticancer therapy
  publication-title: Nat Rev Clin Oncol
– volume: 18
  start-page: 312
  year: 2017
  end-page: 322
  ident: bib4
  article-title: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
  publication-title: Lancet Oncol
– volume: 12
  start-page: 4154
  year: 2006
  end-page: 4162
  ident: bib22
  article-title: c-Met ectodomain shedding rate correlates with malignant potential
  publication-title: Clin Cancer Res
– volume: 28
  start-page: 1850
  year: 2010
  end-page: 1855
  ident: bib26
  article-title: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
  publication-title: J Clin Oncol
– volume: 22
  start-page: 25
  year: 2017
  end-page: 32
  ident: bib31
  article-title: Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients
  publication-title: Oncologist
– volume: 30
  start-page: 191
  year: 2012
  end-page: 199
  ident: bib2
  article-title: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986
  publication-title: J Clin Oncol
– volume: 18
  start-page: 1483
  year: 2017
  end-page: 1492
  ident: bib8
  article-title: First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
  publication-title: Lancet Oncol
– volume: 387
  start-page: 1909
  year: 2016
  end-page: 1920
  ident: bib3
  article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
  publication-title: Lancet
– volume: 389
  start-page: 67
  year: 2017
  end-page: 76
  ident: bib7
  article-title: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
  publication-title: Lancet
– volume: 57
  start-page: 1872
  year: 2016
  end-page: 1879
  ident: bib21
  article-title: Repeatability of quantitative 18F-NaF PET: a multicenter study
  publication-title: J Nucl Med
– volume: 37
  start-page: 2592
  year: 2019
  end-page: 2600
  ident: bib10
  article-title: Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy
  publication-title: J Clin Oncol
– volume: 24
  start-page: 1223
  year: 2014
  end-page: 1231
  ident: bib29
  article-title: Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma
  publication-title: Thyroid
– volume: 376
  start-page: 1015
  year: 2017
  end-page: 1026
  ident: bib5
  article-title: Pembrolizumab as second-line therapy for advanced urothelial carcinoma
  publication-title: N Engl J Med
– volume: 35
  start-page: 591
  year: 2017
  end-page: 597
  ident: bib16
  article-title: Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial
  publication-title: J Clin Oncol
– volume: 81
  start-page: 581
  year: 2015
  end-page: 592
  ident: bib28
  article-title: Rapid modification of the bone microenvironment following short-term treatment with cabozantinib in vivo
  publication-title: Bone
– volume: 151
  start-page: 170
  year: 2015
  end-page: 177
  ident: bib30
  article-title: Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib
  publication-title: JAMA Dermatol
– volume: 37
  year: 2019
  ident: bib11
  article-title: CALGB 90601 (Alliance): randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma
  publication-title: Proc Am Soc Clin Oncol
– volume: 31
  start-page: 3639
  year: 2013
  end-page: 3646
  ident: bib18
  article-title: Cabozantinib in progressive medullary thyroid cancer
  publication-title: J Clin Oncol
– volume: 96
  start-page: 295
  year: 2014
  end-page: 303
  ident: bib33
  article-title: Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2
  publication-title: J Leukoc Biol
– volume: 24
  start-page: 422
  year: 2013
  end-page: 425
  ident: bib14
  article-title: Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
  publication-title: Anticancer Drugs
– volume: 47
  start-page: 178
  year: 2020
  end-page: 184
  ident: bib20
  article-title: 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab
  publication-title: Eur J Nucl Med Mol Imaging
– volume: 31
  start-page: 724
  year: 2013
  end-page: 730
  ident: bib12
  article-title: Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer
  publication-title: J Clin Oncol
– volume: 8
  start-page: 1
  year: 2012
  end-page: 9
  ident: bib34
  article-title: Role of IL-10 in urinary bladder carcinoma and bacillus calmette-guerin immunotherapy
  publication-title: Am J Immunol
– volume: 36
  year: 2018
  ident: bib9
  article-title: First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)
  publication-title: Proc Am Soc Clin Oncol
– volume: 373
  start-page: 1814
  year: 2015
  end-page: 1823
  ident: bib17
  article-title: Cabozantinib versus everolimus in advanced renal-cell carcinoma
  publication-title: N Engl J Med
– volume: 113
  start-page: 429
  year: 2014
  end-page: 436
  ident: bib15
  article-title: Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
  publication-title: BJU Int
– volume: 351
  start-page: 781
  year: 2004
  end-page: 791
  ident: bib25
  article-title: Circulating tumor cells, disease progression, and survival in metastatic breast cancer
  publication-title: N Engl J Med
– volume: 11
  start-page: 175
  year: 2013
  end-page: 181
  ident: bib13
  article-title: Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer
  publication-title: Clin Genitourin Cancer
– volume: 379
  start-page: 54
  year: 2018
  end-page: 63
  ident: bib19
  article-title: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
  publication-title: N Engl J Med
– volume: 106
  year: 2014
  ident: bib27
  article-title: Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib
  publication-title: J Natl Cancer Inst
– volume: 84
  start-page: 1708
  year: 2015
  end-page: 1714
  ident: bib24
  article-title: Viable tumor volume: volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer
  publication-title: Eur J Radiol
– volume: 15
  start-page: 77
  year: 2017
  end-page: 85
  ident: bib23
  article-title: A phase II clinical trial of TRC105 (anti-endoglin antibody) in adults with advanced/metastatic urothelial carcinoma
  publication-title: Clin Genitourin Cancer
– volume: 35
  start-page: 2117
  year: 2017
  end-page: 2124
  ident: bib6
  article-title: Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study
  publication-title: J Clin Oncol
– volume: 23
  start-page: 4602
  year: 2005
  end-page: 4608
  ident: bib1
  article-title: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
  publication-title: J Clin Oncol
– volume: 350
  start-page: 985
  year: 2015
  end-page: 990
  ident: bib32
  article-title: Patrolling monocytes control tumor metastasis to the lung
  publication-title: Science
– volume: 376
  start-page: 1015
  year: 2017
  ident: 10.1016/S1470-2045(20)30202-3_bib5
  article-title: Pembrolizumab as second-line therapy for advanced urothelial carcinoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1613683
– volume: 351
  start-page: 781
  year: 2004
  ident: 10.1016/S1470-2045(20)30202-3_bib25
  article-title: Circulating tumor cells, disease progression, and survival in metastatic breast cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa040766
– volume: 106
  year: 2014
  ident: 10.1016/S1470-2045(20)30202-3_bib27
  article-title: Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/dju033
– volume: 24
  start-page: 1223
  year: 2014
  ident: 10.1016/S1470-2045(20)30202-3_bib29
  article-title: Cabozantinib-induced thyroid dysfunction: a review of two ongoing trials for metastatic bladder cancer and sarcoma
  publication-title: Thyroid
  doi: 10.1089/thy.2013.0621
– volume: 350
  start-page: 985
  year: 2015
  ident: 10.1016/S1470-2045(20)30202-3_bib32
  article-title: Patrolling monocytes control tumor metastasis to the lung
  publication-title: Science
  doi: 10.1126/science.aac9407
– volume: 35
  start-page: 591
  year: 2017
  ident: 10.1016/S1470-2045(20)30202-3_bib16
  article-title: Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.70.7398
– volume: 113
  start-page: 429
  year: 2014
  ident: 10.1016/S1470-2045(20)30202-3_bib15
  article-title: Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)
  publication-title: BJU Int
  doi: 10.1111/bju.12437
– volume: 387
  start-page: 1909
  year: 2016
  ident: 10.1016/S1470-2045(20)30202-3_bib3
  article-title: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)00561-4
– volume: 35
  start-page: 2117
  year: 2017
  ident: 10.1016/S1470-2045(20)30202-3_bib6
  article-title: Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2016.71.6795
– volume: 96
  start-page: 295
  year: 2014
  ident: 10.1016/S1470-2045(20)30202-3_bib33
  article-title: Induction of immunomodulatory monocytes by human mesenchymal stem cell-derived hepatocyte growth factor through ERK1/2
  publication-title: J Leukoc Biol
  doi: 10.1189/jlb.3A0513-242R
– volume: 81
  start-page: 581
  year: 2015
  ident: 10.1016/S1470-2045(20)30202-3_bib28
  article-title: Rapid modification of the bone microenvironment following short-term treatment with cabozantinib in vivo
  publication-title: Bone
  doi: 10.1016/j.bone.2015.08.003
– volume: 31
  start-page: 3639
  year: 2013
  ident: 10.1016/S1470-2045(20)30202-3_bib18
  article-title: Cabozantinib in progressive medullary thyroid cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.48.4659
– volume: 37
  issue: suppl 15
  year: 2019
  ident: 10.1016/S1470-2045(20)30202-3_bib11
  article-title: CALGB 90601 (Alliance): randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma
  publication-title: Proc Am Soc Clin Oncol
– volume: 84
  start-page: 1708
  year: 2015
  ident: 10.1016/S1470-2045(20)30202-3_bib24
  article-title: Viable tumor volume: volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer
  publication-title: Eur J Radiol
  doi: 10.1016/j.ejrad.2015.05.026
– volume: 37
  start-page: 2592
  year: 2019
  ident: 10.1016/S1470-2045(20)30202-3_bib10
  article-title: Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.19.01140
– volume: 28
  start-page: 1850
  year: 2010
  ident: 10.1016/S1470-2045(20)30202-3_bib26
  article-title: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.25.4599
– volume: 379
  start-page: 54
  year: 2018
  ident: 10.1016/S1470-2045(20)30202-3_bib19
  article-title: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1717002
– volume: 11
  start-page: 175
  year: 2013
  ident: 10.1016/S1470-2045(20)30202-3_bib13
  article-title: Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2012.10.001
– volume: 31
  start-page: 724
  year: 2013
  ident: 10.1016/S1470-2045(20)30202-3_bib12
  article-title: Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2012.42.5215
– volume: 22
  start-page: 25
  year: 2017
  ident: 10.1016/S1470-2045(20)30202-3_bib31
  article-title: Phase II and biomarker study of cabozantinib in metastatic triple-negative breast cancer patients
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2016-0229
– volume: 16
  start-page: 356
  year: 2019
  ident: 10.1016/S1470-2045(20)30202-3_bib35
  article-title: Regulatory T cells in cancer immunosuppression - implications for anticancer therapy
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-019-0175-7
– volume: 23
  start-page: 4602
  year: 2005
  ident: 10.1016/S1470-2045(20)30202-3_bib1
  article-title: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2005.07.757
– volume: 36
  issue: suppl 15
  year: 2018
  ident: 10.1016/S1470-2045(20)30202-3_bib9
  article-title: First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)
  publication-title: Proc Am Soc Clin Oncol
– volume: 15
  start-page: 77
  year: 2017
  ident: 10.1016/S1470-2045(20)30202-3_bib23
  article-title: A phase II clinical trial of TRC105 (anti-endoglin antibody) in adults with advanced/metastatic urothelial carcinoma
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2016.05.010
– volume: 30
  start-page: 191
  year: 2012
  ident: 10.1016/S1470-2045(20)30202-3_bib2
  article-title: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2011.37.3571
– volume: 24
  start-page: 422
  year: 2013
  ident: 10.1016/S1470-2045(20)30202-3_bib14
  article-title: Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy
  publication-title: Anticancer Drugs
  doi: 10.1097/CAD.0b013e32835efe78
– volume: 18
  start-page: 1483
  year: 2017
  ident: 10.1016/S1470-2045(20)30202-3_bib8
  article-title: First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30616-2
– volume: 373
  start-page: 1814
  year: 2015
  ident: 10.1016/S1470-2045(20)30202-3_bib17
  article-title: Cabozantinib versus everolimus in advanced renal-cell carcinoma
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1510016
– volume: 57
  start-page: 1872
  year: 2016
  ident: 10.1016/S1470-2045(20)30202-3_bib21
  article-title: Repeatability of quantitative 18F-NaF PET: a multicenter study
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.177295
– volume: 8
  start-page: 1
  year: 2012
  ident: 10.1016/S1470-2045(20)30202-3_bib34
  article-title: Role of IL-10 in urinary bladder carcinoma and bacillus calmette-guerin immunotherapy
  publication-title: Am J Immunol
  doi: 10.3844/ajisp.2012.1.9
– volume: 389
  start-page: 67
  year: 2017
  ident: 10.1016/S1470-2045(20)30202-3_bib7
  article-title: Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32455-2
– volume: 151
  start-page: 170
  year: 2015
  ident: 10.1016/S1470-2045(20)30202-3_bib30
  article-title: Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib
  publication-title: JAMA Dermatol
  doi: 10.1001/jamadermatol.2014.2734
– volume: 12
  start-page: 4154
  year: 2006
  ident: 10.1016/S1470-2045(20)30202-3_bib22
  article-title: c-Met ectodomain shedding rate correlates with malignant potential
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-0250
– volume: 47
  start-page: 178
  year: 2020
  ident: 10.1016/S1470-2045(20)30202-3_bib20
  article-title: 18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-019-04483-5
– volume: 18
  start-page: 312
  year: 2017
  ident: 10.1016/S1470-2045(20)30202-3_bib4
  article-title: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(17)30065-7
– reference: 32645283 - Lancet Oncol. 2020 Aug;21(8):1005-1006. doi: 10.1016/S1470-2045(20)30236-9.
SSID ssj0017105
Score 2.5827413
Snippet Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by decreasing regulatory T...
SummaryBackgroundCabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by...
Summary Background Cabozantinib is a multikinase inhibitor of MET, VEGFR, AXL, and RET, which also has an effect on the tumour immune microenvironment by...
SourceID unpaywall
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1099
SubjectTerms Adult
Aged
Anilides - therapeutic use
Antineoplastic Agents - therapeutic use
Axl protein
Bladder cancer
Cancer therapies
Carcinoma, Transitional Cell - drug therapy
Chemotherapy
Creatinine
Drug dosages
Drug Resistance, Neoplasm - drug effects
FDA approval
Female
Genitourinary tract
Hematology, Oncology, and Palliative Medicine
Humans
Hypophosphatemia
Immune checkpoint inhibitors
Immunomodulation
Immunomodulators
Immunoregulation
Immunotherapy
Inhibitor drugs
Kinases
Lymphocytes T
Male
Metastases
Metastasis
Middle Aged
Patients
Phosphatase
Platinum
Platinum Compounds - therapeutic use
Protein Kinase Inhibitors - therapeutic use
Proteinuria
Pyridines - therapeutic use
Radiation therapy
Solid tumors
Suppressor cells
Targeted cancer therapy
Thyroid cancer
Toxicity
Tumors
Urologic Neoplasms - drug therapy
Urothelial carcinoma
Vascular endothelial growth factor receptors
SummonAdditionalLinks – databaseName: Health & Medical Collection (ProQuest)
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELagSDwOiFdLoCAjcQCpZhM7ib1cKlRRVUhwgUp7sxzHEStls2GzESoHfjszieNWaqFccnAyieWZ2J_HM_MR8jrJMwOgTTAZ55altnRMOcyVAehgC8FNXg0Bsl_yk9P00yJbeIdb58MqpzlxmKjLtUUf-YynAk-VchUftj8Yskbh6aqn0LhJbiUAVdCq5SJsuBI5hjAmqYwZll0_z-CZfQ2Nb3j8VgBo4kz8bW26jD3vkTt905qzn6auL6xHxw_IfQ8k6YdR8w_JDdc8Irc_-6Pyx-T3Eaj3l0EiiGVBlw31FVQ7iq5X2mIMXNOvGPRiM3DunNGV2xpMMFpa2m8wM6sG46QW2Yaa9cq8p6ahyLbFwHJcfUDRzVA7NsR3ugPafocVkXI6EIE8IafHH78dnTBPtsAsbBG3rHJFxpFuPBdFNldOFXNjMXckL0tAhQKaisyIVDnYY9lYVkIZV8a5qgopqioRu2SnWTfuKaHSzRW0OwSXaQwvtllhuCoFl3MsZxORdBpmbX0lciTEqHUIOUPtaNQOXPSgHS0i8i6ItWMpjusE8kmHesozhZlRw2JxnaC8StB1_v_udKI7ruNRGoV5PIiCpAqSHsKM0OR_Pro_mZkO3zm3-oi8CrdhBsBjHdO4dY_P4DYSSWMisjeaZxgfAOfQOcUjMgv2emnwuqu68-zf3XlO7nL0PAyhkPtkZ7vp3QuAZ9vi5fAP_gFeAS63
  priority: 102
  providerName: ProQuest
Title Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1470204520302023
https://www.clinicalkey.es/playcontent/1-s2.0-S1470204520302023
https://dx.doi.org/10.1016/S1470-2045(20)30202-3
https://www.ncbi.nlm.nih.gov/pubmed/32645282
https://www.proquest.com/docview/2430073680
https://www.proquest.com/docview/2423066748
https://www.ncbi.nlm.nih.gov/pmc/articles/8236112
UnpaywallVersion submittedVersion
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: ACRLP
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1474-5488
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: AKRWK
  dateStart: 20000501
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20250802
  omitProxy: true
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 7X7
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1474-5488
  dateEnd: 20250802
  omitProxy: true
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: BENPR
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Public Health Database
  customDbUrl:
  eissn: 1474-5488
  dateEnd: 20250802
  omitProxy: true
  ssIdentifier: ssj0017105
  issn: 1470-2045
  databaseCode: 8C1
  dateStart: 20000901
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/publichealth
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLZGKwF74DpYYVRG4gGkuU3sXFzeRrVpQqKaJiqVp8h2Ha0idaumEdoe-O2ckxuIDY29RFGSL3HiE_uzfc75CHnnR6EC0iZY7EWGBWZumbQYKwPUwWjBVZSWDrKT6HQafJ6Fsx3iN7EwpdO-0YuBy5YDt7gofSvXSzNs_MSGqNDto65wN8I1pQ7pTidnR9_KKKLYY5hevdoPGLBx-TtqZ5i3F7zn3gcBRIkz8a_-6Drf3CUPCrdWlz9Ulv3RB508JudN6SvXk--DYqsH5uqvxI53er0n5FHNSOlRdeop2bHuGbn_pV5zf05-jsFOrhQqSiw0XThap2LNKc7h0jU607liyeDVNqV4zyVd2q3CSKWFocUGQ7wysHJqULbIrZbqI1WOomwXAxO02SHF-YrMstJR1B7S9QV0rZTTUlFkj0xPjr-OT1mt2sAMjDW3LLU65KhbHgkdjqSVeqQMBqFE8znQSwGHdKhEIC0M1owXp0IqO_cimepYpKkvXpCOWzm7T2hsRxKOW2SpgQc3NqFWXM4Fj0eYF6dHgqbuElOnNEdljSxpfdewyhOsctgkZZUnokcGLWxd5fS4DRA1hpE0AavQxCbQ69wGjG8C2rxuKPLET3KeeBUawdwroYCULbLmQhXH-Z-HHjS2m7TP4YHARdlIej3ytj0NTQmuDylnVwVeg-NRVJ_pkZeVzbffB1g-FE7yHhm2P8G1j5ffVJxXd0a8Jg85zmqUbpYHpLPdFPYNUL-t7pN78SyGrRz7fdL9dDw5O-_XDcAvg4BP_Q
linkProvider Unpaywall
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB6VIlE4IN4sFDASSCDVZGPvw0FCCBWqlD4utFJuxuv1ikibTcgmqsKBn8RvZGZfRWqhXHrJwdnZHXnG4xl7Zj6AF_0oNOi0SR77keWBTR1Xjmpl0HWwiRQmyqoE2cNoeBx8HoWjNfjV1sJQWmVrEytDnU4tnZH3RCDpVilS_vvZd06oUXS72kJo1Gqx51YnGLKV73Y_onxfCrHz6Wh7yBtUAW4xFlrwzCWhIFztSCbhQDmVDIylIokoTdH9kTiUhEYGymEwYf04k8q41I9UlsQyy_oS33sFriI7AfXqj0ddgNeP65TJfhD7nNq8n1YM9b50g6-E_1qikya4_NteeNbXvQEby2JmVicmz__Y_3Zuwc3GcWUfak27DWuuuAPXDpqr-bvwcxvV6Ych4IlxwsYFazq2loyOetmMcu6K5YQjF_MK42fFJm5hqKBpbNlyTpVgOS4GZgndqJhOzFtmCkboXhw11eVbjI41cserfFK3xWbfcAdmglXAI_fg-FLEcB_Wi2nhHgKL3UDhuCNnNvDxxTZMjFCpFPGA2ud4ELTTrG3T-ZwAOHLdpbiRdDRJB390JR0tPXjTkc3q1h8XEUStDHVb14qWWOPmdBFhfB6hKxt7Uuq-LoX2a2oiFn5FipSqo2xcptoV-p-PbrZqprvvnK4yD553f6PFoWskU7jpkp6hsJVAajx4UKtnNz8YDCBzSnjQ6_T1zOSV57Hz6N_sPION4dHBvt7fPdx7DNcFnXpUaZibsL6YL90TdA0XydNqPTL4etkG4DcL0ms9
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3daxQxEB9qhaoP4renVSMoKDTeXrIfOUFEWo_WahG0cG9pNpvFg7298_aWcj74h_nXObNfFVqtL325h9zObsh8ZCaZmR_As0EYGHTaJI-80HLfJo4rR7Uy6DrYWAoTplWC7EG4e-h_GAfjNfjV1sJQWmVrEytDncwsnZH3hS_pVilUXj9t0iI-74zezr9zQpCim9YWTqMWkX23OsbwrXizt4O8fi7E6P3X7V3eIAxwi3HRkqcuDgRhbIcyDobKqXhoLBVMhEmCrpDEoTgw0lcOAwvrRalUxiVeqNI4kmk6kPjeS3A5kr6kdLJo3AV7g6hOnxz4kcep5ftJ9VD_Szf4QngvJTpsgsu_7Yun_d5rcKXM52Z1bLLsj71wdAOuN04se1dL3U1Yc_kt2PjUXNPfhp_bKFo_DIFQTGI2yVnTvbVgdOzL5pR_l5dTjrNYVHg_KzZ1S0PFTRPLygVVhWWoGMwS0lE-m5rXzOSMkL44Sq3LthgdcWSOV7mlbovNv-FuzASrQEjuwOGFsOEurOez3N0HFrmhwnFHjq3v4YttEBuhEimiIbXS6YHfLrO2TRd0AuPIdJfuRtzRxB380RV3tOzBq45sXrcBOY8gbHmo2xpXtMoaN6rzCKOzCF3R2JZCD3QhtFdTE7HwKlKkVB1l4z7VbtH_fHSzFTPdfedE43rwtPsbrQ9dKZnczUp6hkJYAqzpwb1aPLv1wcAAJ6dED_qdvJ5avOKs6Tz493SewAaqvv64d7D_EK4KOgCpMjI3YX25KN0j9BKX8eNKHRkcXbT-_warxW94
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1La9wwEBZhA21z6DvNtmlRoYcWIq9X8kPbWwgNodBQShfSk5C0MjH1as16TUkO_e2d8aulSUlzMcb2Z8vWWPokzcxHyJtpEmsgbYKlYWJZZBeOSYexMkAdrBFcJ1njIHuanMyjj2fx2RaZ9rEwjdO-NXngi2Xg8_PGt7Jc2knvJzZBhe4p6gpvJ7imNCLb89PPh9-aKKI0ZJhevd2PGLBx-TtqZ1INF7zl4TsBRIkz8a_-6Crf3CF3a1_qix-6KP7og44fkC996VvXk-9BvTGBvfwrseOtXu8hud8xUnrYnnpEtpx_TO586tbcn5CfR2AnlxoVJXJDc0-7VKwVxTlcWqIzna-XDF5t3Yj3XNCl22iMVMotrdcY4lWAlVOLskV-tdTvqfYUZbsYmKArDijOVxSONY6i7oCW59C1Uk4bRZGnZH784evRCetUG5iFseaGZc7EHHXLE2HimXTSzLTFIJRksQB6KeCQibWIpIPBmg3TTEjtFmEiM5OKLJuKXTLyK-_2CE3dTMJxhyw1CuHGNjaay4Xg6Qzz4oxJ1Nedsl1Kc1TWKNTgu4ZVrrDKYaOaKldiTIIBVrY5PW4CJL1hqD5gFZpYBb3OTcD0OqCruoaiUlNVcRW2aATzsIECUg7Ijgu1HOd_Hrrf264ansMjgYuyiQzH5PVwGpoSXB_S3q1qvAbHo6g-MybPWpsfvg-wfCic5GMyGX6CKx-vuq44z2-NeEHucZzVaNws98los67dS6B-G_Oq-9l_AXANTK8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cabozantinib+in+patients+with+platinum-refractory+metastatic+urothelial+carcinoma%3A+an+open-label%2C+single-centre%2C+phase+2+trial&rft.jtitle=The+lancet+oncology&rft.au=Apolo%2C+Andrea+B&rft.au=Nadal%2C+Rosa&rft.au=Tomita%2C+Yusuke&rft.au=Davarpanah%2C+Nicole+N&rft.date=2020-08-01&rft.eissn=1474-5488&rft.volume=21&rft.issue=8&rft.spage=1099&rft_id=info:doi/10.1016%2FS1470-2045%2820%2930202-3&rft_id=info%3Apmid%2F32645282&rft.externalDocID=32645282
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-2045&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-2045&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-2045&client=summon